Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis.

Chen, Dinghua; Niu, Yue; Liu, Fei; Yang, Yue; Wang, Xue; Li, Ping; Chen, Xiangmei

Chen, Dinghua; Niu, Yue; Liu, Fei; Yang, Yue; Wang, Xue; Li, Ping; Chen, Xiangmei.

Afiliación

Chen D; Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Niu Y; Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Liu F; Department of Urology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang Y; Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Wang X; Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Li P; Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Chen X; Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Beijing, China.

Front Pharmacol ; 14: 1163908, 2023.

Article en En | MEDLINE | ID: mdl-37292157

Palabras clave

adverse event; anemia; chronic kidney disease; erythropoiesis-stimulating agent; hypoxia-inducible factor prolyl hydroxylase inhibitors; renal dialysis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Systematic_reviews Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google